John G. Harpel

An Assay for Transforming Growth Factor-β Using Cells Transfected with a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct

Mayumi Abé, John G. Harpel, Christine N. Metz et al. · Analytical Biochemistry · 1994 · 757 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +10

Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells.

Robert Flaumenhaft, Mayumi Abé, Yasufumi Sato et al. · The Journal of Cell Biology · 1993 · 237 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +6

Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1

John S. Munger, John G. Harpel, Filippo G. Giancotti et al. · Molecular Biology of the Cell · 1998 · 237 citations

Life Sciences, Cell Biology, Molecular Biology +17

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Rubén Niesvizky, David Jayabalan, Paul J. Christos et al. · Blood · 2007 · 183 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma

Tomer M. Mark, Jessica Stern, Jessica Furst et al. · Biology of Blood and Marrow Transplantation · 2008 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +17